India Ranbaxy shares sink after cholesterol drug recall
Shares in Indian drug giant Ranbaxy fell as much as four percent on Monday following news of a second recall of its cholesterol-busting generic drug. It was the latest blow for the New Delhi-based drugmaker, majority-owned by Japan’s Daiichi Sankyo, that is already reeling from a string of US Food and Drug Administration (FDA) import bans involving manufacturing safety worries. "The actual …
FDA News – Yahoo News Search Results
More From Around the Web
Check out these Articles
- Flamel Technologies Announces FDA Approval of Vazculep
- The Facts on the FDA's New Tobacco Rule
- How Sweet It Is: All About Sugar Substitutes
- FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Child...
- Vaccines for Children: Information for Parents and Caregivers
- FDA Encourages More Participation, Diversity in Clinical Trials
- Teva Receives FDA Approval for Vantrela ER (hydrocodone bitartrate) Extende...
- FDA Approves Liletta (levonorgestrel-releasing intrauterine system) to Prev...
- My Dog Has Cancer: What Do I Need to Know?
- Controlling Cholesterol with Statins
- Beware of False or Misleading Claims for Treating Autism
- FDA Approves Qbrelis (lisinopril) Oral Solution for Pediatric Patients 6 Ye...
- FDA Expands Approval of Spiriva Respimat (tiotropium bromide) Inhalation Sp...
- FDA Historians Share Lessons From Agency’s Past
- HITLAB Completes GCP Audit for FDA Smart Device & App Compliance
- FDA Approves Flublok Quadrivalent Influenza Vaccine
- Scopes That Spread UCLA 'Superbug' Were Awaiting FDA Clearance